Featured Editorial

81. Tracking 4 Payload Trends In Drug Delivery Development 1/22/2024

    Amid new research and development in nanocarriers, market attention has shifted toward payloads and enhancing compatibility. This discussion explores the latest trends and includes a research database.

82. Liposome Drug Delivery: Global Trends & Market Forecast 1/19/2024

    Liposomes possess the ability to encapsulate drugs of both hydrophilic and hydrophobic nature. They can be tailored to target tissues or cells, enabling precise drug delivery. Let's examine how it works, applications, and new market insights.

83. Is FDA's COVID Container Closure System Guidance Useful Post-Pandemic? 1/9/2024

    The COVID-era guidance is designed to help manufacturers make container closure system changes quickly when facing supply constraints. It may be useful when evaluating risks beyond the pandemic.

84. Tackling 3 Challenges In Developing An Inhaled Gene Therapy 1/5/2024

    Inhalers hold great potential for delivery of high concentrations of gene therapy directly into the lung. This article shares the experiences of a team who have worked on the development of a gene therapy to treat cystic fibrosis.

85. Drug Delivery Systems: Measurement System Analysis Using Continuous Gage R&R Studies, Part 3 12/20/2023

    This is the third article in a series of three articles. It continues the discussion of measurement system analysis using continuous gage R&D studies by sharing a generic example using Minitab. Study setup, the role of the study director, analysis, and case studies are examined.

86. 4 Strategies To Formulate Poorly Soluble APIs 12/18/2023

    One of the toughest challenges facing small molecule drug development today is poor solubility of the API. No single technique has universal application, so several strategies exist. This article examines four notable strategies.

87. Key Regulatory-Fueled Updates On Combination Products As We Enter 2024 12/15/2023

    In late November, AFDO/RAPS held their annual Combination Products Summit in Fort Worth, TX. The meeting is co-sponsored by the FDA with heavy involvement from the Office of Combination Products, and its representatives covered several themes on the subject as we prepare to enter 2024.

88. Best Practices For Preformulation In Drug Development 12/14/2023

    Preformulation testing encompasses all studies performed on a new drug compound in order to produce useful information for subsequent formulation of a suitable drug dosage form. There is preformulation across the stages of drug discovery, early development, and late development. The route of administration dictates what is important.

89. Midline Catheters Show Fastest Growth Rate In Vascular Access: A Global Market Analysis 12/12/2023

    In many situations, midline catheters present a superior choice compared to short peripheral catheters, which are suitable for brief indwelling periods, and PICCs, which carry a higher risk of central line-associated bloodstream infection (CLABSI) and are more complex to insert. Let's examine new market research.

90. The RNA Therapeutics Race: How Can Pharma Stay Ahead Of The Wave? 12/5/2023

    With more than 970 RNA therapies currently in the development pipeline, the market presents an exciting prospect. This article shares the key attributes of RNA therapies that are paving the way for personalized medicine, novel delivery mechanisms, and more.